Cargando…
Implementation and outcomes of a severe acute respiratory coronavirus virus 2 (SARS-CoV-2) monoclonal antibody treatment program at an academic medical center serving a high-risk patient population
| Autores principales: | , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Cambridge University Press
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9495403/ https://www.ncbi.nlm.nih.gov/pubmed/36168464 http://dx.doi.org/10.1017/ash.2021.165 |
| _version_ | 1784794009227493376 |
|---|---|
| author | Borgetti, Scott A. Gross, Alan E. Kottler, Janey Patel, Kenil Paek, Jamie Mena Lora, Alfredo J. Oikle, Diane Jeffries, Delisa Radosta, Jon |
| author_facet | Borgetti, Scott A. Gross, Alan E. Kottler, Janey Patel, Kenil Paek, Jamie Mena Lora, Alfredo J. Oikle, Diane Jeffries, Delisa Radosta, Jon |
| author_sort | Borgetti, Scott A. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9495403 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2021 |
| publisher | Cambridge University Press |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-94954032022-09-26 Implementation and outcomes of a severe acute respiratory coronavirus virus 2 (SARS-CoV-2) monoclonal antibody treatment program at an academic medical center serving a high-risk patient population Borgetti, Scott A. Gross, Alan E. Kottler, Janey Patel, Kenil Paek, Jamie Mena Lora, Alfredo J. Oikle, Diane Jeffries, Delisa Radosta, Jon Antimicrob Steward Healthc Epidemiol Letter to the Editor Cambridge University Press 2021-06-24 /pmc/articles/PMC9495403/ /pubmed/36168464 http://dx.doi.org/10.1017/ash.2021.165 Text en © The Society for Healthcare Epidemiology of America 2021 https://creativecommons.org/licenses/by/4.0/This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited. |
| spellingShingle | Letter to the Editor Borgetti, Scott A. Gross, Alan E. Kottler, Janey Patel, Kenil Paek, Jamie Mena Lora, Alfredo J. Oikle, Diane Jeffries, Delisa Radosta, Jon Implementation and outcomes of a severe acute respiratory coronavirus virus 2 (SARS-CoV-2) monoclonal antibody treatment program at an academic medical center serving a high-risk patient population |
| title | Implementation and outcomes of a severe acute respiratory coronavirus virus 2 (SARS-CoV-2) monoclonal antibody treatment program at an academic medical center serving a high-risk patient population |
| title_full | Implementation and outcomes of a severe acute respiratory coronavirus virus 2 (SARS-CoV-2) monoclonal antibody treatment program at an academic medical center serving a high-risk patient population |
| title_fullStr | Implementation and outcomes of a severe acute respiratory coronavirus virus 2 (SARS-CoV-2) monoclonal antibody treatment program at an academic medical center serving a high-risk patient population |
| title_full_unstemmed | Implementation and outcomes of a severe acute respiratory coronavirus virus 2 (SARS-CoV-2) monoclonal antibody treatment program at an academic medical center serving a high-risk patient population |
| title_short | Implementation and outcomes of a severe acute respiratory coronavirus virus 2 (SARS-CoV-2) monoclonal antibody treatment program at an academic medical center serving a high-risk patient population |
| title_sort | implementation and outcomes of a severe acute respiratory coronavirus virus 2 (sars-cov-2) monoclonal antibody treatment program at an academic medical center serving a high-risk patient population |
| topic | Letter to the Editor |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9495403/ https://www.ncbi.nlm.nih.gov/pubmed/36168464 http://dx.doi.org/10.1017/ash.2021.165 |
| work_keys_str_mv | AT borgettiscotta implementationandoutcomesofasevereacuterespiratorycoronavirusvirus2sarscov2monoclonalantibodytreatmentprogramatanacademicmedicalcenterservingahighriskpatientpopulation AT grossalane implementationandoutcomesofasevereacuterespiratorycoronavirusvirus2sarscov2monoclonalantibodytreatmentprogramatanacademicmedicalcenterservingahighriskpatientpopulation AT kottlerjaney implementationandoutcomesofasevereacuterespiratorycoronavirusvirus2sarscov2monoclonalantibodytreatmentprogramatanacademicmedicalcenterservingahighriskpatientpopulation AT patelkenil implementationandoutcomesofasevereacuterespiratorycoronavirusvirus2sarscov2monoclonalantibodytreatmentprogramatanacademicmedicalcenterservingahighriskpatientpopulation AT paekjamie implementationandoutcomesofasevereacuterespiratorycoronavirusvirus2sarscov2monoclonalantibodytreatmentprogramatanacademicmedicalcenterservingahighriskpatientpopulation AT menaloraalfredoj implementationandoutcomesofasevereacuterespiratorycoronavirusvirus2sarscov2monoclonalantibodytreatmentprogramatanacademicmedicalcenterservingahighriskpatientpopulation AT oiklediane implementationandoutcomesofasevereacuterespiratorycoronavirusvirus2sarscov2monoclonalantibodytreatmentprogramatanacademicmedicalcenterservingahighriskpatientpopulation AT jeffriesdelisa implementationandoutcomesofasevereacuterespiratorycoronavirusvirus2sarscov2monoclonalantibodytreatmentprogramatanacademicmedicalcenterservingahighriskpatientpopulation AT radostajon implementationandoutcomesofasevereacuterespiratorycoronavirusvirus2sarscov2monoclonalantibodytreatmentprogramatanacademicmedicalcenterservingahighriskpatientpopulation |